Clinical efficacy of ultrasound-guided chondroitin polysulfate from bovine trachea combined with fractional CO2 laser in the treatment of scar after burn repair

Article

作者: Huang, Xiaojun ; Chen, Meijie ; Chen, Jiong ; Chen, Xiaofang ; Zhou, Jianjun

IntroductionOne common and very upsetting side effect of burn injuries is scarring, which presents serious difficulties for patients and medical professionals alike.AimTo assess a new therapeutic approach for treating scars following burn repair procedures in terms of its clinical efficacy.Material and methodsThis method administers Hirudoid under ultrasound guidance in addition to fractional CO₂ laser treatment. An extensive analysis of the effects of this combination treatment on functional results, patient satisfaction, and scar appearance is being conducted as part of this research. Fractional CO₂ laser treatment is utilized for its capacity to stimulate collagen remodelling and decrease scar hypertrophy, while Hirudoid, a topical medicine containing heparinoid, is used to minimize inflammation and enhance tissue healing. Enrolling patients who have had burn repair surgery is the goal of a quasi-experimental study. Conventional scar care methods are performed on the control group, whereas the experimental group is treated with fractional CO₂ laser therapy after applying Hirudoid under ultrasound guidance. Throughout the research period, clinical evaluations are carried out on a regular basis. These evaluations cover scar features, pain thresholds, and patient-reported results.ResultsThe first findings show that the experimental group significantly outperformed the control group in terms of overall look, pigmentation, and scar texture. Functional examinations point to possible improvements in terms of scar flexibility and the range of motion, while patient-reported outcomes show improved satisfaction with the combination therapy. In order to guarantee the combination therapy's viability and tolerance in a clinical context, its side effects and safety profiles are also extensively assessed. In order to improve scar management following burn healing, the study intends to provide important insights into the creation of more patient-friendly and successful therapies.ConclusionsA potential approach to enhancing the clinical results of burn scar treatment is the study of fractional CO₂ laser therapy in conjunction with ultrasound-guided Hirudoid. Enhancing scar management tactics via the combination of sophisticated technology and therapy modalities may eventually improve the quality of life for burn injury victims.

2019-10-02·Drug Metabolism Reviews2区 · 医学

Systemic drugs with impact on osteoarthritis

2区 · 医学

Review

作者: Baciut, Grigore ; Mester, Alexandru ; Maxim, Andrei ; Apostu, Dragos ; Onisor, Florin ; Bran, Simion ; Piciu, Andra ; Baciut, Mihaela ; Benea, Horea ; Pasca, Roxana D. ; Oltean-Dan, Daniel ; Lucaciu, Ondine

Articular cartilage has a complex structure and metabolism which allow for a proper movement within joints. Nevertheless, several systemically administered pharmacological agents have been proved to improve the anabolic response in the case of cartilage lesions. Alendronate, glucosamine, chondroitin sulfate, hyaluronic acid, collagen hydrolysate, vitamin C, vitamin D, aspirin and strontium ranelate have shown positive results in clinical trials. On the other hand, calcitonin, risedronate, doxycycline, and celecoxib did not slow the progression of cartilage lesions in clinical trials. Other systemic drugs or supplements such as teriparatide, leptin, zoledronic acid, bevacizumab, atorvastatin, omega-3 fatty acid, naringin, MSM, selenium, zinc, magnesium, resveratrol, donepezil, naproxen, etodolac, ursodeoxycholic acid (UDCA), lithium chloride, and rebamipide showed positive results in in vitro and animal studies but clinical trials are needed to confirm the positive impact on cartilage repair. A number of molecules, not currently available on the market, have also shown promising results in cartilage healing, such as licofelone, sclerostin, cyclopamine, cyclodextrin polysulfate, AG-041R, osteoprotegerin, rhMK, β-cryptoxanthine, NF-κb essential modulator binding domain (NBD), TGF-β-neutralizing antibody, osteogenic protein-1 (BMP-7), fibroblast growth factor 2 (FGF2), and RhBMP-2. Currently available systemic drugs that impair cartilage healing are represented by corticosteroids, vitamin A, and fluoroquinolones.

100 项与 Cyclodextrin polysulphate 相关的药物交易

登录后查看更多信息